-
ASAM Applauds Bipartisan Legislation to Close the Medicare Coverage Gap for Community-Based Residential Addiction Treatment
Full story -
The ASAM Weekly for August 6th, 2024
Rapid Initiation of Injectable Extended-Release Naltrexone for Opioid Use Disorder: A Time for Paradigm Shift in Treatment ProtocolsFull story -
Guest Editorial: Rapid Initiation of Injectable Extended-Release Naltrexone for Opioid Use Disorder: A Time for Paradigm Shift in Treatment Protocols
The opioid crisis remains a critical public health issue in the United States, contributing to over 80,000 opioid overdose deaths in 2023 alone.Full story -
ASAM and KYSAM Urge KBML to Stop Proposed Treatment Rules, Call for New Workgroup to Form
Full story -
The ASAM Weekly for July 30th, 2024
Guest Editorial: Does Rescheduling Cannabis Make Sense?Full story -
Medicare Improves SUD Coverage in 2025, but Critical Gaps Remain
CMS publishes important 2025 proposals for Addiction Medicine.Full story -
Guest Editorial: Does Rescheduling Cannabis Make Sense?
On May 16, the Department of Justice (DOJ) proposed moving marijuana from Schedule I to Schedule III of the Controlled Substances Act. Between now and November’s election, there will be considerable discussion regarding rescheduling.Full story -
The ASAM Weekly for July 23rd, 2024
Guest Editorial: To Address the Fentanyl Crisis, Greater Access to Methadone Is NeededFull story -
ASAM Releases 2024 Mid-Year State Legislative Report
Full story -
Guest Editorial: To Address the Fentanyl Crisis, Greater Access to Methadone Is Needed
Over the past several years, the increasing prevalence of fentanyl in the drug supply has created an unprecedented overdose death rate and other devastating consequences.Full story -
To Save Lives, ASAM Calls for Policies to Ensure Pharmacists Can Dispense Medications for Addiction Treatment Without Undue Delay, While Urging Caution in Allowing Pharmacists the Ability to Prescribe
Full story -
ASAM Submits Comments on DEA's Proposed Rescheduling of Marijuana
ASAM comments on marijuana rescheduling proposal.Full story -
The ASAM Weekly for July 16th, 2024
Benzodiazepine use in relation to long-term dementia riskFull story -
The ASAM Weekly for July 9th, 2024
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trialFull story -
The ASAM Weekly for July 2nd, 2024
Global status report on alcohol and health and treatment of substance use disordersFull story -
ASAM Offers Tips on the Essentials of Effective Op-ed Writing
ASAM Advocacy has developed seven fundamental tips for op-ed writing to assist members.Full story -
With Coalition, ASAM Requests $40 Million for DOL's EBSA in Labor-HHS Appropriations Bill
Twenty four organizations signed a letter, spearheaded by Mental Health America, requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.Full story -
The ASAM Weekly for June 25th, 2024
Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose DeathsFull story -
ASAM Joins Letter Urging Finalization of 2023 Proposed Parity Regulations
ASAM joined a letter signed by 40 organizations requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations.Full story -
The ASAM Weekly for June 18th, 2024
Piloting a Hospital-Based Rapid Methadone Initiation Protocol for FentanylFull story